Harbor BioSciences of the US has signed an umbrella agreement with the China Institute of Pharmaceutical Industry (CIPI), a Sinopharma subsidiary, to distribute generic drugs outside China. The non-exclusive deal does not cover any specific drugs. Sub-licenses will be negotiated separately for one or more CIPI drugs at a time, with Harbor receiving a royalty on sales. More details....

Stock Symbol: (OTCBB: HRBR)